Rigel Pharmaceuticals, Inc. (RIGL)

Market Cap	533.32M +45.4%
Revenue (ttm)	294.28M +64.1%
Net Income	367.02M +1,999.1%
EPS	19.48 +1,867.7%
Shares Out	18.47M
PE Ratio	1.48
Forward PE	7.18
Dividend	n/a
Ex-Dividend Date	n/a

Volume	354,349
Open	28.81
Previous Close	29.52
Day's Range	28.24 - 29.20
52-Week Range	15.50 - 52.24
Beta	1.17
Analysts	Strong Buy
Price Target	43.20 (+49.64%)
Earnings Date	Mar 3, 2026

About RIGL

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company’s commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 29, 2000
• Employees: 164
• Stock Exchange: NASDAQ
• Ticker Symbol: RIGL
• Website: https://www.rigel.com

Financial Performance

In 2025, Rigel Pharmaceuticals's revenue was $294.28 million, an increase of 64.15% compared to the previous year's $179.28 million. Earnings were $367.02 million, an increase of 1999.08%.

Analyst Summary

According to 5 analysts, the average rating for RIGL stock is "Strong Buy." The 12-month stock price target is $43.2, which is an increase of 49.64% from the latest price.

Price Target

$43.2

(49.64% upside)

Analyst Consensus: Strong Buy